AR076732A1 - Formulaciones farmaceuticas elaboradas por nanoencapsulacion y/o complejacion - Google Patents
Formulaciones farmaceuticas elaboradas por nanoencapsulacion y/o complejacionInfo
- Publication number
- AR076732A1 AR076732A1 ARP090102671A ARP090102671A AR076732A1 AR 076732 A1 AR076732 A1 AR 076732A1 AR P090102671 A ARP090102671 A AR P090102671A AR P090102671 A ARP090102671 A AR P090102671A AR 076732 A1 AR076732 A1 AR 076732A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclodextrins
- beta
- nanoencapsulation
- complexation
- cyclodextrin
- Prior art date
Links
- 238000010668 complexation reaction Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 235000017471 coenzyme Q10 Nutrition 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940097362 cyclodextrins Drugs 0.000 abstract 2
- -1 sulfobutyl ether beta-cyclodextrins Chemical class 0.000 abstract 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005515 coenzyme Substances 0.000 abstract 1
- 239000005516 coenzyme A Substances 0.000 abstract 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 abstract 1
- 229940093530 coenzyme a Drugs 0.000 abstract 1
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical class O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 abstract 1
- 239000000412 dendrimer Substances 0.000 abstract 1
- 229920000736 dendritic polymer Polymers 0.000 abstract 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000004530 micro-emulsion Substances 0.000 abstract 1
- 239000007908 nanoemulsion Substances 0.000 abstract 1
- 239000002077 nanosphere Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuestos elaborados por nanoencapsulacion y/o complejacion de los principios activos tales como integrantes de la familia de los jasmonatos, ciclopentanonas, sufasalaxina L-Arginina, coenzimas Q10 o CoQ10, Coenzima A. Reivindicacion 1: Compuestos elaborados por nanoencapsulacion y/o complejacion caracterizados porque comprenden como ingrediente activo integrantes de la familia de los jasmonatos, puros o no, conjugados o no con aminas (con substitucion del radical éster por un radical amina) nanoencapsulados en y/o complejados con (i) ciclodextrinas alfa, beta y gamma, ciclodextrinas modificadas o no, e incluyendo a las ciclodextrinas hidroxipropil-beta-ciclodextrina, beta-ciclodextrina metilada aleatoriamente, y sulfobutiléter beta-ciclodextrinas), (ii) liposomas compuestos de fosfatidil-colina, (iii) ácidos grasos y sus derivados, (iv) colesterol, modificado artificialmente o no, (v) polímeros biodegradables y absorbibles, (vi) dendrímeros, (vii) nanoesferas, (viii) talosferas, (ix) nanoemulsiones y (x) microemulsiones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0804172-5A BRPI0804172A2 (pt) | 2008-07-15 | 2008-07-15 | compostos quìmicos formados a partir de nanoencapsulamentos e complexação de elementos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076732A1 true AR076732A1 (es) | 2011-07-06 |
Family
ID=41550752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102671A AR076732A1 (es) | 2008-07-15 | 2009-07-15 | Formulaciones farmaceuticas elaboradas por nanoencapsulacion y/o complejacion |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20110305731A1 (es) |
| EP (1) | EP2320879A4 (es) |
| JP (5) | JP2011527989A (es) |
| KR (2) | KR20170076788A (es) |
| CN (1) | CN102215832A (es) |
| AR (1) | AR076732A1 (es) |
| BR (1) | BRPI0804172A2 (es) |
| CA (1) | CA2730876A1 (es) |
| MX (1) | MX347677B (es) |
| RU (1) | RU2011101961A (es) |
| WO (1) | WO2010006392A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0804172A2 (pt) * | 2008-07-15 | 2010-07-06 | Pereira Lopes Jose Emilio Fehr | compostos quìmicos formados a partir de nanoencapsulamentos e complexação de elementos |
| WO2012114196A1 (pt) * | 2011-02-25 | 2012-08-30 | Nanocare Technologies, Inc. | Formulação farmacêutica compreendendo compostos da família dos jasmonatos |
| RU2014114931A (ru) | 2011-09-16 | 2015-10-27 | Нанокэа Текнолоджиз, Инк. | Композиции соединений жасмонатов и способы применения |
| KR20170125811A (ko) | 2014-12-31 | 2017-11-15 | 나노케어 테크놀로지스 인코퍼레이티드 | 자스모네이트 유도체 및 그 조성물 |
| CN107551275B (zh) * | 2017-09-12 | 2020-06-12 | 山西大学 | 一种磁性纳米药物载体的制备及其负载盐酸阿霉素的方法 |
| CN114171111B (zh) * | 2021-11-12 | 2024-06-28 | 中检科健(天津)检验检测有限责任公司 | 一种化学物质p-糖蛋白相互作用qsar筛选方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2073507T3 (es) * | 1989-04-12 | 1995-08-16 | Procter & Gamble | Composiciones de productos solidos de consumo que contienen complejos con ciclodextrina en forma de pequeñas particulas. |
| CA2013485C (en) * | 1990-03-06 | 1997-04-22 | John Michael Gardlik | Solid consumer product compositions containing small particle cyclodextrin complexes |
| JP3568325B2 (ja) * | 1996-07-12 | 2004-09-22 | 株式会社ノエビア | 抗アンドロゲン剤及び養毛剤並びに毛髪用化粧料 |
| JP3596835B2 (ja) * | 1996-08-13 | 2004-12-02 | 株式会社ノエビア | 養毛剤 |
| KR20010013609A (ko) * | 1997-06-09 | 2001-02-26 | 데이비드 엠 모이어 | 가향 조성물, 및 체취 및 과도한 습기의 감소 방법 |
| US6790815B1 (en) * | 1998-07-10 | 2004-09-14 | Procter & Gamble Company | Amine reaction compounds comprising one or more active ingredient |
| CA2439953A1 (en) * | 2001-03-08 | 2002-09-19 | Mark D. Bednarski | Stabilized therapeutic and imaging agents |
| US6469061B1 (en) * | 2001-04-04 | 2002-10-22 | Ramot University Authority For Applied Research And Industrial Development Limited | Jasmonate pharmaceutical composition for treatment of cancer |
| US20030224024A1 (en) * | 2002-02-04 | 2003-12-04 | Jean-Luc Leveque | Compositions comprising cyclopentane derivatives and their use |
| KR100789343B1 (ko) * | 2004-09-07 | 2007-12-28 | 주식회사 엘지생활건강 | 화장용 분체, 그의 제조방법 및 이를 함유하는 메이컵화장품 조성물 |
| US7258878B2 (en) * | 2004-12-20 | 2007-08-21 | Kimberly-Clark Worldwide, Inc. | Anti-microbial composition and methods of use thereof |
| ES2265291B1 (es) * | 2005-07-22 | 2008-03-01 | Universidad De Alcala | Nuevos dendrimeros carbosilanos, su preparacion y sus usos. |
| US20070207981A1 (en) * | 2006-03-06 | 2007-09-06 | Eva Almenar | Micro-encapsulation of volatile compounds into cyclodextrins: a new technology to reduce post harvest losses |
| BRPI0621778A2 (pt) * | 2006-06-13 | 2011-12-20 | Cargill Inc | complexos de inclusão de ciclodextrina de partìcula grande e métodos de preparar os mesmos |
| CA2657375A1 (en) * | 2006-07-10 | 2008-01-17 | Ramot At Tel-Aviv University Ltd. | Combination methods of treating cancer |
| BRPI0604024A (pt) * | 2006-09-01 | 2008-04-22 | Beyond Lifescience Pesquisa De | alimentos para a prevenção do cáncer e composições farmacêuticas à base do jasmonato |
| BRPI0804172A2 (pt) * | 2008-07-15 | 2010-07-06 | Pereira Lopes Jose Emilio Fehr | compostos quìmicos formados a partir de nanoencapsulamentos e complexação de elementos |
-
2008
- 2008-07-15 BR BRPI0804172-5A patent/BRPI0804172A2/pt not_active IP Right Cessation
-
2009
- 2009-05-28 EP EP09797284.8A patent/EP2320879A4/en not_active Withdrawn
- 2009-05-28 RU RU2011101961/15A patent/RU2011101961A/ru not_active Application Discontinuation
- 2009-05-28 CA CA2730876A patent/CA2730876A1/en not_active Abandoned
- 2009-05-28 WO PCT/BR2009/000151 patent/WO2010006392A2/en not_active Ceased
- 2009-05-28 JP JP2011517717A patent/JP2011527989A/ja active Pending
- 2009-05-28 KR KR1020177017059A patent/KR20170076788A/ko not_active Ceased
- 2009-05-28 CN CN2009801263694A patent/CN102215832A/zh active Pending
- 2009-05-28 MX MX2011000400A patent/MX347677B/es active IP Right Grant
- 2009-05-28 KR KR1020117003309A patent/KR101751918B1/ko not_active Expired - Fee Related
- 2009-05-28 US US13/054,110 patent/US20110305731A1/en not_active Abandoned
- 2009-07-15 AR ARP090102671A patent/AR076732A1/es not_active Application Discontinuation
-
2014
- 2014-08-01 JP JP2014157671A patent/JP2014237688A/ja active Pending
-
2016
- 2016-06-01 US US15/170,893 patent/US20160354312A1/en not_active Abandoned
- 2016-07-22 JP JP2016143999A patent/JP2016216496A/ja active Pending
-
2017
- 2017-09-29 JP JP2017189865A patent/JP2018030868A/ja active Pending
-
2019
- 2019-01-04 JP JP2019000267A patent/JP2019070008A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2730876A1 (en) | 2010-01-21 |
| JP2018030868A (ja) | 2018-03-01 |
| MX2011000400A (es) | 2011-04-26 |
| CN102215832A (zh) | 2011-10-12 |
| KR20110031232A (ko) | 2011-03-24 |
| JP2016216496A (ja) | 2016-12-22 |
| EP2320879A4 (en) | 2014-03-05 |
| US20160354312A1 (en) | 2016-12-08 |
| KR101751918B1 (ko) | 2017-06-30 |
| BRPI0804172A2 (pt) | 2010-07-06 |
| US20110305731A1 (en) | 2011-12-15 |
| WO2010006392A2 (en) | 2010-01-21 |
| EP2320879A2 (en) | 2011-05-18 |
| JP2014237688A (ja) | 2014-12-18 |
| WO2010006392A3 (en) | 2010-03-18 |
| RU2011101961A (ru) | 2012-08-20 |
| KR20170076788A (ko) | 2017-07-04 |
| JP2011527989A (ja) | 2011-11-10 |
| JP2019070008A (ja) | 2019-05-09 |
| MX347677B (es) | 2017-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076732A1 (es) | Formulaciones farmaceuticas elaboradas por nanoencapsulacion y/o complejacion | |
| CO6280058A1 (es) | Composicion farmaceutica que comprende una sal de estroncio vitamina d y una ciclodextrina | |
| CY1120780T1 (el) | Μακροκυκλικοι αναστολεις πρωτεασης σερινης της ηπατιτιδας c | |
| Plazzo et al. | Uptake of a fluorescent methyl-β-cyclodextrin via clathrin-dependent endocytosis | |
| CY1118017T1 (el) | Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3 | |
| AR066984A1 (es) | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) | |
| CR20120414A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
| MX2009011247A (es) | Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones. | |
| BRPI0918882A2 (pt) | métodos, sistemas e composições para tolerância aumentada de microorganismo para produção de ácido 3-hidroxipropiônico (3-hp) | |
| WO2011163483A3 (en) | Polymers for biomaterials and therapeutics | |
| BRPI1012141A2 (pt) | conjugado de sirna e método de preparação do mesmo | |
| JP2008189687A5 (es) | ||
| NZ603411A (en) | Pazopanib compositions and their use in treating ocular diseases | |
| BRPI0711481A8 (pt) | derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens | |
| JP2019512019A5 (es) | ||
| CR20140368A (es) | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) | |
| CY1112499T1 (el) | Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων | |
| BR112015015609A2 (pt) | preparação de ésteres de poli alfa-1,3-glucano e seus filmes | |
| JP2009537572A5 (es) | ||
| PE20120029A1 (es) | Composiciones antimicrobianas | |
| BR112014006683A2 (pt) | nanoestrutura que compreende íons de manganês; composição farmacêutica; uso de uma nanopartícula; e nanoestrutura | |
| CY1115196T1 (el) | Αντικαρκινικος παραγων | |
| EP2131849A4 (en) | COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER | |
| JP2017523260A5 (es) | ||
| ECSP077263A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |